CN1882584A - 4－取代的咪唑 - Google Patents

4－取代的咪唑 Download PDF

Info

Publication number
CN1882584A
CN1882584A CNA2004800342450A CN200480034245A CN1882584A CN 1882584 A CN1882584 A CN 1882584A CN A2004800342450 A CNA2004800342450 A CN A2004800342450A CN 200480034245 A CN200480034245 A CN 200480034245A CN 1882584 A CN1882584 A CN 1882584A
Authority
CN
China
Prior art keywords
disease
compound
illness
formula
aromatic ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800342450A
Other languages
English (en)
Chinese (zh)
Inventor
詹姆斯·恩菲尔德
艾菲奥恩·菲利普斯
斯科特·思罗纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1882584A publication Critical patent/CN1882584A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2004800342450A 2003-11-19 2004-11-15 4－取代的咪唑 Pending CN1882584A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0303075A SE0303075D0 (sv) 2003-11-19 2003-11-19 4-substituted imidazoles
SE03030756 2003-11-19

Publications (1)

Publication Number Publication Date
CN1882584A true CN1882584A (zh) 2006-12-20

Family

ID=29729099

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800342450A Pending CN1882584A (zh) 2003-11-19 2004-11-15 4－取代的咪唑

Country Status (13)

Country Link
US (1) US7384954B2 (https=)
EP (1) EP1687303A1 (https=)
JP (1) JP2007511603A (https=)
KR (1) KR20060100426A (https=)
CN (1) CN1882584A (https=)
AU (1) AU2004291457A1 (https=)
BR (1) BRPI0416629A (https=)
CA (1) CA2546096A1 (https=)
IL (1) IL175438A0 (https=)
NO (1) NO20062862L (https=)
SE (1) SE0303075D0 (https=)
WO (1) WO2005049612A1 (https=)
ZA (1) ZA200604018B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103649084A (zh) * 2011-04-20 2014-03-19 国家科学研究中心 1,4-双取代1,2,3-三唑、用于制备其的方法及其诊断性和治疗性用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0303076D0 (sv) * 2003-11-19 2003-11-19 Astrazeneca Ab 5-substituted imidazoles
WO2006065217A1 (en) * 2004-12-16 2006-06-22 Astrazeneca Ab Nicotinic acetycholine receptor ligands

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226000A (en) * 1987-09-10 1991-06-25 Merck Sharp & Dohme Oxadiazolyl-azabicycloheptanes and pharmaceutical compositions
US6599916B2 (en) * 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
EP1311505A2 (en) * 2000-08-21 2003-05-21 PHARMACIA & UPJOHN COMPANY Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
US20020086871A1 (en) 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
FR2832713B1 (fr) * 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
DK1562945T3 (da) * 2002-11-11 2007-03-05 Neurosearch As Hidtil ukendte diazebicykliske biarylderivater

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103649084A (zh) * 2011-04-20 2014-03-19 国家科学研究中心 1,4-双取代1,2,3-三唑、用于制备其的方法及其诊断性和治疗性用途
CN103649084B (zh) * 2011-04-20 2017-03-29 国家科学研究中心 1,4‑双取代1,2,3‑三唑、用于制备其的方法及其诊断性和治疗性用途

Also Published As

Publication number Publication date
JP2007511603A (ja) 2007-05-10
AU2004291457A1 (en) 2005-06-02
KR20060100426A (ko) 2006-09-20
CA2546096A1 (en) 2005-06-02
EP1687303A1 (en) 2006-08-09
SE0303075D0 (sv) 2003-11-19
US20070105896A1 (en) 2007-05-10
ZA200604018B (en) 2007-11-28
BRPI0416629A (pt) 2007-01-16
US7384954B2 (en) 2008-06-10
NO20062862L (no) 2006-08-21
IL175438A0 (en) 2006-09-05
WO2005049612A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
CN1132837C (zh) 螺呋喃并吡啶芳烷基胺、其制法和中间体及其药物组合物和制药用途
CN1662542A (zh) 杂环化合物
CN1675215A (zh) 作为烟碱性乙酰胆碱拮抗剂的芳基取代的二氮杂双环烷烃
CN1423651A (zh) 新的用途和新的n－氮杂双环－酰胺衍生物
CN1662541A (zh) 呋喃基化合物
US6828330B2 (en) Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease
CN1659170A (zh) 噻吩基化合物
CN1211983A (zh) 用于治疗的氨基甲酸的氮杂双环酯
CN1257500A (zh) 作为尼古丁ACh受体上胆碱能配体的9－氮杂双环(3.3.1)壬－2－烯和壬烷衍生物
US6849620B2 (en) N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
US20030232853A1 (en) Azabicyclic compounds for the treatment of disease
US20030130305A1 (en) Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease
CN103649019B (zh) 用于治疗精神分裂症的氘化的1-哌嗪子基-3-苯基-茚满
CN1110496C (zh) 四氢γ－咔啉类化合物
RU2323218C2 (ru) Новые производные 1,4-диазабициклоалкана и фармацевтическая композиция на их основе
CN1784230A (zh) 烟碱性乙酰胆碱受体的正向调节剂
JP6483105B2 (ja) ピペラジン誘導体および医薬としてのその使用
CN1918166A (zh) 烟碱乙酰胆碱受体配体
CN1124266C (zh) 氮杂环辛烷和庚烷衍生物、其制备方法和治疗用途
CN1910190A (zh) 环氨基取代的噻吩并嘧啶和噻吩并吡啶衍生物
CN1882584A (zh) 4－取代的咪唑
CN1914200A (zh) 烟碱性乙酰胆碱受体配件
CN1882583A (zh) 5－取代的咪唑
KR20200029393A (ko) 오렉신 수용체 길항제
CN1914201A (zh) 烟碱乙酰胆碱受体配体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication